Life science becoming ‘growth engine’ following Sigma-Aldrich buy, Merck
Germany’s Merck expects to achieve cost synergies of €90m ($98m) in 2016 from the integration of Sigma-Aldrich which the firm acquired in November.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs